(TheNewswire)
Calgary, Alberta, Canada, June 11, 2024 – TheNewswire – Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the"Company") announces that in an innovative endeavor, Voyageur and Rain Cage Carbon Inc. ("Rain Cage") are followingup on the first commercial creation of a V@C 60 endohedral fullerene (Vanadium atom insidea C 60 molecule). RainCage is now embarking on the next phase of radiology drug development,by utilizing their cutting-edge technology. Rain Cage will begintesting to create on a commercial scale, the encapsulation ofgadolinium, bismuth, and iodine within endohedral fullerenes. Thepioneering work, set to begin later this month, with the objective todevelop a process to create Gd@C 60 , Bi@C 60 , and I@C 60 endohedralfullerenes, targeting the development of highly advanced radiologycontrast agents for Magnetic Resonance Imaging (MRI) and CT scans.These novel compounds, known for their rarity and complex synthesis,hold the promise of transforming medical imaging by significantlyenhancing the precision and clarity of radiological scans.
"We are thrilled to be at theforefront of this groundbreaking initiative that marries cutting-edgenanotechnology with pharmaceutical innovation. Our collaboration withRain Cage in my view marks a pivotal moment in medical science, wherethe development of endohedral fullerenes promises not justadvancements in radiology, but a paradigm shift in how we approachdiagnostic imaging. I believe this is just the beginning of atransformative journey towards revolutionizing healthcare solutionsfor the benefit of patients worldwide," stated Brent Willis, CEO of Voyageur.
Endohedral fullerenes are a class of fullerenes thatenclose an additional atom, ion, or cluster within their inner sphere,exhibiting superior physical and electronic characteristics comparedto regular fullerenes. In the context of radiology drugs, endohedralmetallofullerenes offer a distinct advantage through exceptionalstability and bioavailability, an amplified signal that leads tobetter image clarity and resolution, targeteddelivery and reduced toxicity. These properties have garnered interestin applications such as MRI contrast agents. One notable example isgadolinium endohedral fullerene, featuring gadolinium enclosed in acarbon cage, which displays high proton relaxivity and low toxicity,showing great promise for MRI contrast agents. ( https://pubmed.ncbi.nlm.nih.gov/?term=gadolinium+fullerene+contrast+agent )
Endohedral fullerenes show potential in radiologycontrast applications such as X-ray and CT scans, including acting asMRI contrast agents for superior imaging resolution, aiding inradiopharmaceutical stability andbioavailability, and serving as platforms for targeted drug deliverythrough functionalization with specific targeting molecules.
Endohedral fullerenes are incredibly rare forcommercial applications due to the complex and precise conditionsrequired for their synthesis, making them one of the most valuablematerials in nanotechnology. Rain Cage Carbon has developed a methodto create these high value molecules at scale, an industryfirst.
About Voyageur PharmaceuticalsLtd.
Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium and iodine ActivePharmaceutical Ingredients (API) and offers high-performance,cost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium and iodine contrast market, Voyageuraims to become a key player by producing its own barium, iodine, andfullerene minerals.
Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As Voyageur solidifies its presence inthe market, it plans to transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.
Voyageur is committed to sustainability andenvironmental stewardship. Voyageur envisions a future where reducingcarbon emissions is the norm, and to achieve this, it is buildingstate-of-the-art carbon-capture infrastructure utilising the Rain Cage EDEN TM system . Byinvesting in carbon capture energy sources and sustainablemanufacturing practices, Voyageur aims to increase revenue from carboncaptured “advanced carbon production” to accelerate growth.Voyageur's unwavering commitment to the environment sets it apart as apioneer in the industry.
At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project. Thisproject boasts exceptional grade minerals suitable for thepharmaceutical marketplace.
Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to the final production, Voyageur ensures quality andcost efficiency. With its approach, it embodies the motto of " Fromthe Earth to the Bottle ," highlightingVoyageur's commitment to responsible sourcing and manufacturingpractices.
About Rain Cage Carbon Inc
Rain Cage is a pioneering private Canadian companydedicated to decarbonizing industries by capturing CO 2 and other emissions and transformingthem into advanced carbon. Through its proprietary technology,EDEN™, it offers companies a groundbreaking solution to combatcarbon pollution. Rain Cage's unique approach not only helps mitigateemissions but also harnesses contaminating energy and converts it intoa recyclable technology with countless applications.
For Further Information:
Brent Willis, CEO, | Albert Deslauriers, CFO, |
Brent@vpharma.ca, 403-923-5944 | Albert@vpharma.ca |
info@vpharma.ca |
Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.
Cautionary Statement Regarding “Forward-Looking”Information
Thisnews release may contain certain forward-looking information andstatements, including without limitation, statements pertaining to:the successful encapsulation of gadolinium, bismuth, and iodine withinendohedral fullerenes on a commercial scale, and whether these novelcompounds will significantly enhance the process and clarity ofradiological scans. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties. There canbe no assurance that such information will prove to be accurate, andactual results and future events could differ materially from thoseanticipated in such information. A description of assumptions used todevelop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR+ website at www.sedarplus.ca. Voyageur does notundertake to update any forward-looking information except inaccordance with applicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.